000 03736naa a22005537i 4500
001 UMUN-OA-20261005-MLS-061
003 local
005 20261005174906.0
006 m o d
007 cr||||||||||||
008 261005s2022 xx o u000 0 eng d
024 7 _a10.3389/fbioe.2022.922772
_2doi
035 _a(local)EuropePMC:PMC9237331
040 _alocal
_beng
_clocal
041 0 _aeng
100 0 _aAndreea-Cristina Mirica
_eauthor.
245 1 0 _aLatest Trends in Lateral Flow Immunoassay (LFIA) Detection Labels and Conjugation Process. /
_cAndreea-Cristina Mirica; Dana Stan; Ioana-Cristina Chelcea [and others].
264 1 _a[Place of publication not identified] :
_bFrontiers Media SA,
_c2022.
300 _a1 online resource (1 article).
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
500 _aPublication type: Review article.
500 _aLinked open-access copy: published version.
506 0 _aOpen access; no subscription required for the linked open-access version.
_fUnrestricted online access
_2star
520 3 _aLFIA is one of the most successful analytical methods for various target molecules detection. As a recent example, LFIA tests have played an important role in mitigating the effects of the global pandemic with SARS-COV-2, due to their ability to rapidly detect infected individuals and stop further spreading of the virus. For this reason, researchers around the world have done tremendous efforts to improve their sensibility and specificity. The development of LFIA has many sensitive steps, but some of the most important ones are choosing the proper labeling probes, the functionalization method and the conjugation process. There are a series of labeling probes described in the specialized literature, such as gold nanoparticles (GNP), latex particles (LP), magnetic nanoparticles (MNP), quantum dots (QDs) and more recently carbon, silica and europium nanoparticles. The current review aims to present some of the most recent and promising methods for the functionalization of the labeling probes and the conjugation with biomolecules, such as antibodies and antigens. The last chapter is dedicated to a selection of conjugation protocols, applicable to various types of nanoparticles (GNPs, QDs, magnetic nanoparticles, carbon nanoparticles, silica and europium nanoparticles).
540 _aCreative Commons Attribution (licence family recorded by the source; version not supplied in metadata).
_uhttps://europepmc.org/articles/PMC9237331
546 _aIn English.
588 0 _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 _aCourse allocation: B. Sc. Medical Laboratory Science.
650 4 _aNanoparticles
650 4 _aDiagnostic
650 4 _aBioconjugation
650 4 _aFunctionalization
650 4 _aLfia
653 _aB. Sc. Medical Laboratory Science
653 _aUMUN open access collection
653 _aimmunoassay
655 4 _aReview articles.
700 0 _aDana Stan
_eauthor.
700 0 _aIoana-Cristina Chelcea
_eauthor.
700 0 _aCarmen Marinela Mihailescu
_eauthor.
700 0 _aAugustin Ofiteru
_eauthor.
700 0 _aLorena-Andreea Bocancia-Mateescu
_eauthor.
773 0 _tFrontiers in bioengineering and biotechnology
_gVol. 10, (2022), pages/article 922772
_x2296-4185
856 4 0 _uhttps://europepmc.org/articles/PMC9237331
_yRead open-access publication
_zOpen access.
_70
884 _aCourse selection and automated MARC21 enrichment from Europe PMC metadata.
_g20261005
_khttps://europepmc.org/articles/PMC9237331
_qlocal
942 _n0
999 _c1203
_d1203